Ikena Oncology, Inc. (IKNA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boston, MA, United States. The current CEO is Mark Manfredi.
IKNA has IPO date of 2021-03-26, 10 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $718.82M.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
